Bruker
BRKR today announces an exclusive licensing agreement with Erasmus
Medical Center, Rotterdam, The Netherlands for rapid testing of
beta-lactamase activity using MALDI-TOF technology. This new method is
fully compatible with the well-established Bruker MALDI Biotyper
system, which is used for MALDI-TOF mass spectrometry-based
identification of microorganisms in over 700 clinical and non-clinical
microbiology laboratories worldwide.
“The Bruker MALDI Biotyper System.” (Photo: Business Wire)
In many laboratories, the MALDI Biotyper has replaced classical
biochemical testing for bacterial identification in the past five years
due to the accuracy, speed, extensive species coverage, ease of use and
cost effectiveness of the system. Classical biochemical techniques
depend upon detecting different metabolic properties of
See full press releaseLoading...
Loading...
BRKRBruker Corp
$38.31-5.43%
Edge Rankings
Momentum
13.35
Growth
52.76
Quality
11.24
Value
20.58
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in